Physician profile
Alan G Mckee
NPI 1326068750
$3,589.20
in general payments reported to CMS, 2019-2025
12 companies · $455 in 2025
The $455 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $844 · 2020: $443 · 2021: $588 · 2022: $318 · 2023: $503 · 2024: $438 · 2025: $455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $600 · Food and Beverage: $496 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $600.00 |
| Food and Beverage | $495.65 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $1,335.09 | 2019-2025 | Clariti Contact Lens, Myday Contact Lens, Synergeyes Contact Lens |
| Alcon Vision LLC | $910.56 | 2019-2025 | Air Optix, Tryptyr, Total30 |
| Johnson & Johnson Vision Care, INC. | $811.65 | 2019-2025 | Acuvue |
| Sun Pharmaceutical Industries INC. | $209.99 | 2021-2025 | |
| Bausch & Lomb Americas INC. | $107.34 | 2023-2024 | Infuse, Biotrue One Day, Multi-Focal |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $50.61 | 2019-2021 | |
| Glaukos Corporation | $43.33 | 2024 | Ce-Marked Kxla System |
| Spark Therapeutics, INC. | $36.50 | 2021 | |
| Genzyme Corporation | $35.07 | 2019-2025 | |
| Dompe US, INC. | $18.08 | 2022 | |
| Allergan, INC. | $16.19 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Mckee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.